User login
COPD in Primary Care: Key Consideration for Optimized Management
Contents
Introduction
Barbara P. Yawn, MD, MSc, FAAFP
Dyspnea and Hyperinflation in Chronic Obstructive Pulmonary Disease: Impact on Physical Activity
Nathaniel Marchetti, DO, and Alan Kaplan, MD
Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management
Abebaw Mengistu Yohannes, PhD; Alan Kaplan, MD; and Nicola A. Hanania, MD, MS
Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease
Rajiv Dhand, MD; Tricia Cavanaugh, MD; and Neil Skolnik, MD
Treatment Options for Stable Chronic Obstructive Pulmonary Disease: Current Recommendations and Unmet Needs
Barbara Yawn, DM, MSc, FAAFP; and Victor Kim, MD
Contents
Introduction
Barbara P. Yawn, MD, MSc, FAAFP
Dyspnea and Hyperinflation in Chronic Obstructive Pulmonary Disease: Impact on Physical Activity
Nathaniel Marchetti, DO, and Alan Kaplan, MD
Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management
Abebaw Mengistu Yohannes, PhD; Alan Kaplan, MD; and Nicola A. Hanania, MD, MS
Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease
Rajiv Dhand, MD; Tricia Cavanaugh, MD; and Neil Skolnik, MD
Treatment Options for Stable Chronic Obstructive Pulmonary Disease: Current Recommendations and Unmet Needs
Barbara Yawn, DM, MSc, FAAFP; and Victor Kim, MD
Contents
Introduction
Barbara P. Yawn, MD, MSc, FAAFP
Dyspnea and Hyperinflation in Chronic Obstructive Pulmonary Disease: Impact on Physical Activity
Nathaniel Marchetti, DO, and Alan Kaplan, MD
Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management
Abebaw Mengistu Yohannes, PhD; Alan Kaplan, MD; and Nicola A. Hanania, MD, MS
Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease
Rajiv Dhand, MD; Tricia Cavanaugh, MD; and Neil Skolnik, MD
Treatment Options for Stable Chronic Obstructive Pulmonary Disease: Current Recommendations and Unmet Needs
Barbara Yawn, DM, MSc, FAAFP; and Victor Kim, MD
In the Evolving Mystery of BV, an Innovative Oral Treatment Emerges
Click Here to Read the Supplement
Topics include:
- BV terminology and treatment over time
- Current understanding of BV etiology
- BV consequences
- BV treatments
- Future research needs in BV
Author:
Steven E. Chavoustie, MD, FACOG, CCRP
University of Miami
Miller School of Medicine
Miami, Florida
Click Here to Read the Supplement
Topics include:
- BV terminology and treatment over time
- Current understanding of BV etiology
- BV consequences
- BV treatments
- Future research needs in BV
Author:
Steven E. Chavoustie, MD, FACOG, CCRP
University of Miami
Miller School of Medicine
Miami, Florida
Click Here to Read the Supplement
Topics include:
- BV terminology and treatment over time
- Current understanding of BV etiology
- BV consequences
- BV treatments
- Future research needs in BV
Author:
Steven E. Chavoustie, MD, FACOG, CCRP
University of Miami
Miller School of Medicine
Miami, Florida
Best of 2017: Top News Articles
Rheumatology News Best of 2017: Top News Highlights
Best of 2017: Top News Highlights is a supplement to Rheumatology News that presents some of the top stories published in the newspaper in 2017.
The ideas and opinions expressed in Best of 2017: Top News Highlights do not necessarily reflect those of the Publisher. Frontline Medical Communications Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
Best of 2017: Top News Highlights is a supplement to Rheumatology News that presents some of the top stories published in the newspaper in 2017.
The ideas and opinions expressed in Best of 2017: Top News Highlights do not necessarily reflect those of the Publisher. Frontline Medical Communications Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
Best of 2017: Top News Highlights is a supplement to Rheumatology News that presents some of the top stories published in the newspaper in 2017.
The ideas and opinions expressed in Best of 2017: Top News Highlights do not necessarily reflect those of the Publisher. Frontline Medical Communications Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
Patient-centered risk assessment for ovarian cancer: Individualizing your approach
Neal M. Lonky, MD, MPH
Clinical Professor
Department of Obstetrics
and Gynecology
University of California, Irvine
Physician Lead, Strategic EMR
Documentation and Analysis
Department of Obstetrics
and Gynecology
Member, Board of Directors
Southern California Permanente
Medical Group
Kaiser Permanente
OBG Management Contributing Editor
Jeanine M. Genkinger, PhD, MHS
Associate Professor
Department of Epidemiology
Columbia University Mailman School of Public Health
New York, New York
Leslie M. Randall, MD
Associate Professor
Division of Gynecologic Oncology
University of California, Irvine,
School of Medicine
Devansu Tewari, MD
Division Director, Gynecologic Oncology
Department of Obstetrics and Gynecology
Kaiser Permanente Orange County
Women’s Health Services
Associate Clinical Professor
University of California, Irvine,
School of Medicine
Jason D. Wright, MD
Sol Goldman Associate Professor and Chief, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons
New York, New York
Dr. Lonky reports that he has received grant or research support from Merck & Co.
Dr. Genkinger reports no financial relationships relevant to this article.
Dr. Wright reports that he has served as a consultant to Clovis Oncology and Tesaro Inc.
Dr. Randall and Dr. Tewari report no financial relationships relevant to this article.
Neal M. Lonky, MD, MPH
Clinical Professor
Department of Obstetrics
and Gynecology
University of California, Irvine
Physician Lead, Strategic EMR
Documentation and Analysis
Department of Obstetrics
and Gynecology
Member, Board of Directors
Southern California Permanente
Medical Group
Kaiser Permanente
OBG Management Contributing Editor
Jeanine M. Genkinger, PhD, MHS
Associate Professor
Department of Epidemiology
Columbia University Mailman School of Public Health
New York, New York
Leslie M. Randall, MD
Associate Professor
Division of Gynecologic Oncology
University of California, Irvine,
School of Medicine
Devansu Tewari, MD
Division Director, Gynecologic Oncology
Department of Obstetrics and Gynecology
Kaiser Permanente Orange County
Women’s Health Services
Associate Clinical Professor
University of California, Irvine,
School of Medicine
Jason D. Wright, MD
Sol Goldman Associate Professor and Chief, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons
New York, New York
Dr. Lonky reports that he has received grant or research support from Merck & Co.
Dr. Genkinger reports no financial relationships relevant to this article.
Dr. Wright reports that he has served as a consultant to Clovis Oncology and Tesaro Inc.
Dr. Randall and Dr. Tewari report no financial relationships relevant to this article.
Neal M. Lonky, MD, MPH
Clinical Professor
Department of Obstetrics
and Gynecology
University of California, Irvine
Physician Lead, Strategic EMR
Documentation and Analysis
Department of Obstetrics
and Gynecology
Member, Board of Directors
Southern California Permanente
Medical Group
Kaiser Permanente
OBG Management Contributing Editor
Jeanine M. Genkinger, PhD, MHS
Associate Professor
Department of Epidemiology
Columbia University Mailman School of Public Health
New York, New York
Leslie M. Randall, MD
Associate Professor
Division of Gynecologic Oncology
University of California, Irvine,
School of Medicine
Devansu Tewari, MD
Division Director, Gynecologic Oncology
Department of Obstetrics and Gynecology
Kaiser Permanente Orange County
Women’s Health Services
Associate Clinical Professor
University of California, Irvine,
School of Medicine
Jason D. Wright, MD
Sol Goldman Associate Professor and Chief, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons
New York, New York
Dr. Lonky reports that he has received grant or research support from Merck & Co.
Dr. Genkinger reports no financial relationships relevant to this article.
Dr. Wright reports that he has served as a consultant to Clovis Oncology and Tesaro Inc.
Dr. Randall and Dr. Tewari report no financial relationships relevant to this article.
2018 Directory of VA and DoD Facilities
Management of Acute Coronary Syndromes in Patients with Diabetes
The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today.
Management of Acute Coronary Syndromes in Patients with Diabetes is the fifth eNewsletter in this series.
The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today.
Management of Acute Coronary Syndromes in Patients with Diabetes is the fifth eNewsletter in this series.
The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today.
Management of Acute Coronary Syndromes in Patients with Diabetes is the fifth eNewsletter in this series.
Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome
CME: Current Treatment Strategies for Advanced Prostate Cancer
Click here to read the supplement.
This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.
In this CME supplement, you will learn to:
- Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
- Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
- Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
- Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection
Click here to read the supplement.
After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP
Click here to read the supplement.
This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.
In this CME supplement, you will learn to:
- Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
- Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
- Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
- Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection
Click here to read the supplement.
After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP
Click here to read the supplement.
This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.
In this CME supplement, you will learn to:
- Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
- Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
- Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
- Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection
Click here to read the supplement.
After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP
